All Resources
Read all of the latest breakthroughs, insights, and news from Ginkgo.
BlogDecember 19, 2023
FT011 - Hard, Bad, Bitter: Why I'm Hopeful about AI for BiologyBlogDecember 12, 2023
FT010 - Design and Scale for Engineering BiologyBlogDecember 8, 2023
FT009 - Synthetic Biology for Carbon and ClimateBlogDecember 1, 2023
FT008 - Better food proteins with EncapSBlogNovember 16, 2023
FT007 - EncapS for Screening in Ultra-High ThroughputBlogNovember 9, 2023
FT006 - Abstraction Layers and the Foundry Era of Biotech R&DBlogNovember 2, 2023
FT005 - Improving a Stubborn Enzyme with AI and DataBlogOctober 27, 2023
FT004 - Machine Learning and the New Enzyme Thrift ShopBlogOctober 20, 2023
FT003 - End to End with Circular RNABlogOctober 16, 2023
FT000 - About Foundry TheoryBlogOctober 16, 2023
FT001 - What is a Foundry for Biology?BlogOctober 16, 2023
FT002 - Is Machine Learning the Language of Biology?BlogNovember 9, 2021
Investigational Synthetic Biotic Medicine for Homocystinuria with SynlogicBlogOctober 26, 2021
Advancing Treatments for Orphan and Rare Diseases with Selecta BiosciencesBlogSeptember 21, 2021
The End of the Beginning: Ginkgo Goes PublicBlogSeptember 10, 2021
Developing High-Efficacy Adjuvants for Vaccines with SaponiQxBlogSeptember 7, 2021
Engineering Living Biotherapeutics for Gastrointestinal Health with TantuBlogAugust 12, 2021
Accelerating Production of Essential Medicines with AntheiaBlogAugust 3, 2021
Vertex CEO Dr. Kewalramani to Join Ginkgo BoardBlogMay 14, 2021
Taking Ginkgo Public on NYSE:DNABlogJune 30, 2020
Needle in a Haystack: Looking for Compounds to Treat COVID-19BlogApril 17, 2020
Teaming Up to Improve Antibody Therapeutics for COVID-19BlogApril 15, 2020
Supporting COVID-19 mRNA Vaccine Development with ModernaBlogApril 10, 2020
Project Update: COVID-19 DNA Synthesis
